EPAD

Collaborative #research initiative to improve the chance of successfully preventing #Alzheimer’s #dementia.
Closed project funded by @IHIEurope.

[EPAD @IMI_EPAD]

📢The @IMI_EPAD genomic data is now available on the #ADWorkbench to provide even greater value to the global neuroscience research community.

#openaccess #datasharing @alzdata @aridhia @CenDemPrevent @craig_ritchie68 @IHIEurope

https://t.co/RdjY0n4UqB

[EPAD @IMI_EPAD]

Check out this new paper examining whether performance on Favorites, a computerized test of associative memory, was cross-sectionally associated with AD biomarker status in older adults from the @IMI_EPAD cohort!

@BarcelonaBeta

https://t.co/yxTnARj8AQ

[EPAD @IMI_EPAD]

New paper out utilising MRI imaging and genetic data from participants in multiple cohorts including @IMI_EPAD

Check it out↩️
https://t.co/OCsT8zQakb

[EPAD @IMI_EPAD]

New study out exploring the prevalence of cerebral microbleeds (CMBs) in association with amyloid status, APOE ε4 copy number, and age.

Congratulations to all authors 👏

https://t.co/BuCmC4rZ04

[EPAD @IMI_EPAD]

New study out exploring the potential of sRNAs as biomarkers for Alzheimer's disease, using whole blood
@IMI_EPAD samples.

Congratulations to all authors 👏

https://t.co/P1d6NRCuX7

[EPAD @IMI_EPAD]

📢 New paper out investigating neurodegeneration patterns across CSF Alzheimer’s disease biomarker groups, the association of brain volumes with CSF amyloid and tau status and sex differences in these relationships in a clinical neurology sample 👇

https://t.co/Y63EviQKPy

[EPAD @IMI_EPAD]

👉Welcome to Day 2 of #ADPD2025!

We're pleased that several oral presentations mentioned the @IMI_EPAD project yesterday!

Interested to know more about our data? Stop by booth 16 of @AlzData to see demos of #ADWorkbench!

https://t.co/9FwLQZfIOI

[EPAD @IMI_EPAD]

📢 New paper out aiming to better inform use of Parental Onset of Dementia (POD) as a risk stratification tool in studies of late-onset Alzheimer's disease.

Congratulations to all authors 👍
https://t.co/eTLabo3VrJ

[EPAD @IMI_EPAD]

📢New paper out perfoming a well-powered Brain Wide Association Study of the grey-matter structure in Alzheimer's disease, symptoms and progression, using a meta-analysis across 11 Cohorts including @IMI_EPAD ⤵️

https://t.co/lvIGoel9Gl

[EPAD @IMI_EPAD]

👉Check out this new paper assessing longitudinal brain atrophy and cognitive decline as a function of cerebrospinal fluid (CSF) AD biomarkers in the ALFA and @IMI_EPAD cohorts!

Congratulations to all authors 👏 @Raffaele_C1

https://t.co/lFY1ENKMVU

[Barcelonaβeta Brain Research Center @BarcelonaBeta]

🗞️ Just published!

A new groundbreaking study by Dr. Raffaele Cacciaglia (@Raffaele_C1) has shown that amyloid accumulation on its own can cause brain atrophy and cognitive decline, even without elevated levels of the tau protein.

https://t.co/kn0U8FCzEn

[EPAD @IMI_EPAD]

Check out this new paper "Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study" using data from 15 research and memory clinic studies including @IMI_EPAD

Congratulations to all authors👏

https://t.co/BuCmC4swPC

[AMYPAD @IMI_AMYPAD]

✨New Interview with @emmaluckettneu1, Postdoc Researcher & Data Manager at the Department of Radiology/Nuclear Medicine at the @amsterdamumc.

Don't miss this interview where she shares her @IMI_AMYPAD work & what inspires her the most about research.

https://t.co/a5DvjZVntq

[Cindy Birck @CindyBirck]

So nice to hear Elisabetta Vaudano presenting the neurodegeneration portfolio from @IHIEurope at #34AEC.
@AlzheimerEurope is involved in many of these projects, contributing through communication & public involvement activities and ethics discussions.

[EPAD @IMI_EPAD]

The @IMI_EPAD biobank includes blood, CSF, saliva and urine samples collected over the course of our longitudinal study.

Interested in applying for sample access? Visit our website: https://t.co/26RY34YQSK

#TimeToActOnDementia #TimeToActOnAlzheimers #WorldAlzMonth

[AMYPAD @IMI_AMYPAD]

We had a fantastic day yesterday at the @eumind_congress! If you're attending #EUMind2024, don’t miss @LECollij's presentation today on 'From @IMI_AMYPAD to #EuroPAD – creating a multi-cohort preclinical database to model AD disease trajectories.' #EUMIND

[EPAD @IMI_EPAD]

Today is #WorldAlzheimerDay 🧠

Every 3 seconds someone in the world develops #dementia and there are over 55 million people around the world living with dementia🌍

#WorldAlzMonth #TimeToActOnDementia #TimeToActOnAlzheimers

[EPAD @IMI_EPAD]

For #WorldAlzMonth, we're pleased to present our new @IMI_EPAD paper published in @GreenJournal.

Congratulations @LuigiLorenzini1 & team👋

https://t.co/yVVrzsiZJ2

[Luigi Lorenzini @LuigiLorenzini1]

Happy to see this out after long time and effort we put into it!
Important collaborative work where we examined the interrelationship between systemic vascular factors, cerebrovascular disease and AD pathological changes in non-demented individuals
...

https://t.co/MgeEzsDY49

[EPAD @IMI_EPAD]

The data, bio samples & neuroimaging generated from the @IMI_EPAD study are available for researchers studying the brain & neurodegenerative diseases.

Visit our website for further information⤵️
https://t.co/PQNqpuBw51

#TimeToActOnDementia #TimeToActOnAlzheimers #WorldAlzMonth

[EPAD @IMI_EPAD]

🧠September is World Alzheimer’s Month, an international campaign to raise #dementia awareness and challenge stigma.

🌍Follow along with #WorldAlzMonth!

@AlzDisInt #TimeToActOnDementia #TimeToActOnAlzheimers

[EPAD @IMI_EPAD]

Want to know more about the NeuroToolKit Application developed by Roche Diagnostics & supported by @AlzData?

Check out this paper reporting its testing phase & how this tool could advance research in Alzheimer's disease⤵️
@craig_ritchie68 @JuandoGispert

https://t.co/dqMNjyyCnZ